Casebia Therapeutics bolsters leadership by bringing in two new faces
pharmafile | September 8, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Bayer, CRISPR Therapeutics, Casebia Therapeutics, biotech, drugs, pharma, pharmaceutical
Casebia therapeutics, a joint venture between Bayer and CRISPR Therapeutics, has moved to strengthen its leadership team by bringing in Michael Laska as Vice President of CMC Development and Manufacturing and Ileen Winick, as Vice President of Human Resources.
The company is only a little under two years old and bolstering its leadership team makes sense as the company continues to develop its partnerships, such as its move in April 2017 to collaborate with StrideBio and to sign a licensing agreement in March of the same year with MaxCyte.
Casebia explained the decision behind the appointments: “We are pleased to have Michael and Ileen join our effort to unlock the full potential of gene editing therapeutics,” said Jim Burns, President and Chief Executive Officer of Casebia. “Michael is a recognized leader in building manufacturing processes to support the creation of novel therapeutic modalities. Ileen has a strong track record of helping to build the team needed to support the growth of innovative organizations in biotech and beyond. Together, their expertise will help shape our growth and enable us to scale to help patients with genetic disease.”
Laska arrives at the company having plenty of previous experience in the pharmaceutical industry, with 13 years of experience working at MSD through various roles. He eventually finished his career at MSD in the position as Director of BioProcess R&D, a role he held for 4 years. The position he held prior to Casebia was at Moderna Therapeutics as Head of Process Development.
For Winick, she has held numerous Human Resources positions, including as Manager of Human Resources at the Genetics Institute for three years. Prior to joining Casebia, she held the role of Vice President, Human Resources at Ovascience – a company focused on providing fertility treatments.
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …